The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.
Khurum Hayat Khan
No relevant relationships to disclose
Li Yan
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
Janusz Mezynski
No relevant relationships to disclose
Amita Patnaik
Research Funding - MK-2206-10
Victor Moreno
No relevant relationships to disclose
Kyriakos P. Papadopoulos
Research Funding - Merck
Chris R. Garrett
No relevant relationships to disclose
Michael Ong
No relevant relationships to disclose
Keith A. Shannon
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
Anne Morosky
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
Eric H. Rubin
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
Ernestina Tetteh
Employment or Leadership Position - Merck
Stock Ownership - Merck
Jeffrey Skolnik
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Ian C. Smith
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Paul D. Smith
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Johann Sebastian De Bono
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Anthony W. Tolcher
Consultant or Advisory Role - AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Ambit BioSciences (U); Amgen (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Bayer (U); BIND Biosciences (U); Biogen Idec (U); Celgene (U); Curis (U); Daiichi Sankyo (U); Dendreon (U); Dicerna (U); EMD Serono (U); Endo Pharmaceuticals (U); Enzon (U); Exelixis (U); FivePrime (U); Galapagos (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); ImClone Systems (U); Insert Therapeutics (U); Intellikine (U); Invivis (U); Janssen Pharmaceutical (U); Johnson & Johnson (U); Merck (U); Micromet (U); Nektar (U); Neumedicines (U); Novartis (U); Onyx (U); Otsuka (U); Pfizer (U); PPD Development (U); ProNAi (U); Regeneron (U); Sanofi (U); Spectrum Pharmaceuticals (U); SuperGen (U); Symphogen (U); Triphase accelerator crop (U); Vaccinex (U); Veeda Oncology (U); Zyngenia (U)
Research Funding - Merck